MX365242B - El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim. - Google Patents
El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.Info
- Publication number
- MX365242B MX365242B MX2013013308A MX2013013308A MX365242B MX 365242 B MX365242 B MX 365242B MX 2013013308 A MX2013013308 A MX 2013013308A MX 2013013308 A MX2013013308 A MX 2013013308A MX 365242 B MX365242 B MX 365242B
- Authority
- MX
- Mexico
- Prior art keywords
- cxcr4 antagonists
- certain
- disorders
- compositions
- treating
- Prior art date
Links
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 title abstract 2
- 208000010115 WHIM syndrome Diseases 0.000 abstract 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486632P | 2011-05-16 | 2011-05-16 | |
| PCT/US2012/037970 WO2012158707A1 (en) | 2011-05-16 | 2012-05-15 | Use of cxcr4 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013013308A MX2013013308A (es) | 2014-02-27 |
| MX365242B true MX365242B (es) | 2019-05-28 |
Family
ID=81755014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013308A MX365242B (es) | 2011-05-16 | 2012-05-15 | El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150030561A1 (https=) |
| EP (1) | EP2709991B1 (https=) |
| JP (1) | JP2014513727A (https=) |
| KR (3) | KR20140045411A (https=) |
| CN (1) | CN103596935A (https=) |
| BR (1) | BR112013029482A2 (https=) |
| ES (1) | ES2831049T3 (https=) |
| MX (1) | MX365242B (https=) |
| PL (1) | PL2709991T3 (https=) |
| RU (1) | RU2638802C2 (https=) |
| WO (1) | WO2012158707A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5829372B2 (ja) | 2005-05-02 | 2015-12-09 | ジェンザイム・コーポレーション | 神経代謝性疾患のための遺伝子治療 |
| US9419667B2 (en) | 2013-04-16 | 2016-08-16 | Skyworks Solutions, Inc. | Apparatus and methods related to conformal coating implemented with surface mount devices |
| US9375406B2 (en) * | 2014-09-30 | 2016-06-28 | Taigen Biotechnology Co., Ltd. | Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| CA3008279A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| WO2017112894A1 (en) | 2015-12-22 | 2017-06-29 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| GB201604213D0 (en) * | 2016-03-11 | 2016-04-27 | Proximagen Ltd | Drug combination and its use in therapy |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3472129A4 (en) * | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| KR20240151726A (ko) * | 2016-09-08 | 2024-10-18 | 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. | 판코니 빈혈 환자를 위한 유전자 치료 |
| CN109988153B (zh) * | 2017-12-29 | 2021-11-19 | 深圳夏浠湾医药科技有限公司 | 一种川芎嗪衍生物及其制备方法和应用 |
| WO2019200167A1 (en) | 2018-04-11 | 2019-10-17 | Rocket Pharmaceuticals, Ltd. | Compositions and methods for stem cell transplant |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
| KR20230088917A (ko) * | 2020-10-20 | 2023-06-20 | 이오엠 파마슈티컬스 인코포레이티드 | Covid-19 치료용 eom613 |
| CN113662937B (zh) * | 2021-10-09 | 2022-08-23 | 江苏省人民医院（南京医科大学第一附属医院） | Plerixafor在上调EFTUD2表达和抑制HBV药物中的用途 |
| CN116675708A (zh) * | 2023-04-23 | 2023-09-01 | 华南师范大学 | 一类氧化响应的大环化合物、大环配合物及其应用 |
| WO2025122961A1 (en) * | 2023-12-08 | 2025-06-12 | X4 Pharmaceuticals, Inc. | Methods for treating neutropenia |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (https=) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
| US6001826A (en) | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| GB9105489D0 (en) | 1991-03-15 | 1991-05-01 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| US5612478A (en) | 1995-03-30 | 1997-03-18 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
| US5606053A (en) | 1995-05-02 | 1997-02-25 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| WO2000009152A1 (en) | 1998-08-14 | 2000-02-24 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
| JP2002506830A (ja) | 1998-03-13 | 2002-03-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 治療的ケモカイン受容体アンタゴニスト |
| ES2156581T5 (es) | 1998-03-30 | 2015-01-21 | Northwest Biotherapeutics, Inc. | Aplicaciones terapéuticas y diagnósticas basadas en el papel del gen CXCR-4 en la tumorigénesis |
| US6365583B1 (en) | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| AU2334301A (en) | 1999-12-17 | 2001-06-25 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| CA2335109A1 (en) | 2000-04-12 | 2001-10-12 | Chemokine Therapeutics Corporation | Cxcr4 agonist treatment of hematopoietic cells |
| US20070160574A1 (en) | 2000-04-12 | 2007-07-12 | Ahmed Merzouk | Design of CXC chemokine analogs for the treatment of human diseases |
| EP1286684B1 (en) | 2000-05-09 | 2004-04-28 | The University Of British Columbia | use of cxcr4 antagonists for treating autoimmune diseases and cancer |
| MXPA02012067A (es) | 2000-06-05 | 2004-08-19 | Univ Columbia | Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico. |
| DE60136476D1 (de) | 2000-09-29 | 2008-12-18 | Anormed Inc | -stickstoffhaltigen zyklischen polyaminen und deren verbindungen |
| US20040157818A1 (en) | 2001-05-24 | 2004-08-12 | Mikiro Yanaka | Cxcr4-antagonistic drugs composed of nitrogen-containing compound |
| DK1411918T3 (da) | 2001-07-31 | 2012-04-23 | Genzyme Global S A R L | Fremgangsmåder til at mobilisere progenitor/stamceller |
| US20030221931A1 (en) | 2002-02-28 | 2003-12-04 | Steve Marsh | Sliding device |
| US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| AU2003261723A1 (en) | 2002-08-27 | 2004-03-19 | Takeda Chemical Industries, Ltd. | Cxcr4 antagonist and use thereof |
| US7504422B2 (en) | 2003-04-02 | 2009-03-17 | Taigen Biotechnology Co. Ltd. | Polyamine compounds |
| US7399776B2 (en) | 2003-04-02 | 2008-07-15 | Taigen Biotechnology | Polyamine compounds for treating chemokine receptor mediated diseases |
| JP2008509928A (ja) | 2004-08-13 | 2008-04-03 | アノーメド インコーポレイテッド | 前駆／幹細胞を動員するためのケモカインの組み合わせ |
| US7501526B2 (en) | 2005-01-20 | 2009-03-10 | Taigen Biotechnology | Synthesis of polyamine compounds |
| WO2006095542A1 (ja) | 2005-03-04 | 2006-09-14 | Kureha Corporation | アミン系化合物を含む医薬組成物 |
| WO2007022385A2 (en) * | 2005-08-18 | 2007-02-22 | Novartis Ag | Use of cxcr4 binding molecules for the treatment of whim syndrome |
| US20070043012A1 (en) | 2005-08-19 | 2007-02-22 | Bridger Gary J | Methods to enhance chemotherapy |
| WO2007047882A2 (en) * | 2005-10-18 | 2007-04-26 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Combination of cxcr4 antagonist and morphogen to increase angiogenesis |
| CA2643209A1 (en) | 2006-02-24 | 2007-09-20 | Genzyme Corporation | Methods for increasing blood flow and/or promoting tissue regeneration |
| US8080659B2 (en) | 2006-07-11 | 2011-12-20 | Emory University | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| US20100003224A1 (en) | 2006-08-02 | 2010-01-07 | Genzyme Corporation | Combination Therapy |
| CN101500595A (zh) | 2006-08-07 | 2009-08-05 | 健赞股份有限公司 | 组合治疗 |
| PL2132221T3 (pl) | 2007-02-28 | 2011-04-29 | Polyphor Ltd | Przyłączone do matrycy peptydomimetyki |
| CA2728124C (en) | 2008-06-23 | 2014-12-02 | Research In Motion Limited | Method for delivering device and server capabilities |
| WO2010025416A1 (en) | 2008-08-29 | 2010-03-04 | Genzyme Corporation | Cxcr4 antagonists for kidney injury |
| JP2012516353A (ja) * | 2009-01-30 | 2012-07-19 | ジェンザイム・コーポレーション | 血液系悪性腫瘍を治療するための方法及び組成物 |
-
2012
- 2012-05-15 KR KR1020137033309A patent/KR20140045411A/ko not_active Ceased
- 2012-05-15 EP EP12786739.8A patent/EP2709991B1/en active Active
- 2012-05-15 WO PCT/US2012/037970 patent/WO2012158707A1/en not_active Ceased
- 2012-05-15 CN CN201280024014.6A patent/CN103596935A/zh active Pending
- 2012-05-15 KR KR1020217023153A patent/KR20210094672A/ko not_active Ceased
- 2012-05-15 JP JP2014511460A patent/JP2014513727A/ja not_active Withdrawn
- 2012-05-15 BR BR112013029482A patent/BR112013029482A2/pt not_active IP Right Cessation
- 2012-05-15 US US14/118,144 patent/US20150030561A1/en not_active Abandoned
- 2012-05-15 RU RU2013155601A patent/RU2638802C2/ru active
- 2012-05-15 KR KR1020207003632A patent/KR20200016407A/ko not_active Ceased
- 2012-05-15 ES ES12786739T patent/ES2831049T3/es active Active
- 2012-05-15 PL PL12786739T patent/PL2709991T3/pl unknown
- 2012-05-15 MX MX2013013308A patent/MX365242B/es active IP Right Grant
-
2020
- 2020-07-13 US US16/927,856 patent/US20210161859A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103596935A (zh) | 2014-02-19 |
| KR20140045411A (ko) | 2014-04-16 |
| RU2013155601A (ru) | 2015-06-27 |
| KR20210094672A (ko) | 2021-07-29 |
| BR112013029482A2 (pt) | 2016-08-09 |
| EP2709991B1 (en) | 2020-09-02 |
| RU2638802C2 (ru) | 2017-12-15 |
| JP2014513727A (ja) | 2014-06-05 |
| PL2709991T3 (pl) | 2021-04-06 |
| EP2709991A4 (en) | 2014-10-01 |
| ES2831049T3 (es) | 2021-06-07 |
| EP2709991A1 (en) | 2014-03-26 |
| US20210161859A1 (en) | 2021-06-03 |
| KR20200016407A (ko) | 2020-02-14 |
| US20150030561A1 (en) | 2015-01-29 |
| MX2013013308A (es) | 2014-02-27 |
| WO2012158707A1 (en) | 2012-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX365242B (es) | El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim. | |
| PH12020500255A1 (en) | Use of nk-1 receptor antagonist serlopitant in pruritus | |
| AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| GB201017345D0 (en) | Receptor antagonists | |
| SG2014011654A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
| IL234884A0 (en) | Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use | |
| IL230705A0 (en) | Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use | |
| ZA201401097B (en) | Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof | |
| MX2015008813A (es) | Composiciones y metodos para contrarrestar la inhibicion del factor xa. | |
| WO2014153495A3 (en) | Novel stat3 inhibitors | |
| MX2016007947A (es) | Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con caracteristicas melancolicas. | |
| MX2014000878A (es) | Composiciones y metodos para reducir la incidencia de transtornos digestivos equinos. | |
| EP2665488A2 (en) | Methods and kits for assessing heparanase procoagulant activity, compositions comprising heparanase, and methods for the treatment of coagulation-related disorders | |
| IL271284A (en) | Methods for treating or preventing asthma by administering an antagonist to -il-r4 | |
| MX2012011207A (es) | Combinaciones para el tratamiento de enfermedades obstructivas de las vias respiratorias. | |
| IL227475A0 (en) | Methods and kits for evaluating the pro-coagulation activity of heparanase' Preparations containing heparanase and methods for the treatment of disorders related to coagulation | |
| UA96048C2 (ru) | Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |